Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.

University of Copenhagen

Status: Enrolling

Conditions: Healthy

Treatments: Drug: Salmeterol + amino acid availability; Drug: Salmeterol + placebo; Drug: Placebo + placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT06654986

SALM_chron

Details and patient eligibility

About

The purpose of the project is to investigate the effect of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation in young healthy men and women.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-40
• Physically active >5 hours a week
• Maximum oxygen uptake classified as high or very high

Exclusion criteria

• Active smoker currently or within the past 5 years
• Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women)
• Chronic or acute illness deemed by the responsible study physician to affect the test parameters
• Deviation from the study protocol
• Lean mass index >21 kg/m²
• Pregnancy
• Smoker
• Blood donation during the past 3 months

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

36 participants in 3 patient groups, including a placebo group

Salmeterol + amino acid availability

Experimental group

Description:

The participants will be administered salmeterol from an inhaler device and amino acid availability (protein powder in a shaker) daily during a 6-week intervention.

Treatment:

Drug: Salmeterol + amino acid availability

Salmeterol + placebo

Experimental group

Description:

The participants will be administered salmeterol from an inhaler device. Furthermore they will be administered placebo (carbo fuel in a shaker) daily during a 6-week intervention.

Placebo + placebo

Placebo Comparator group

Description:

The participants will be administered placebo from an inhaler device. Furthermore they will be administered placebo (carbo fuel in a shaker) daily during a 6-week intervention.

Treatment:

Drug: Placebo + placebo